Americans pay more for prescription drugs than patients in any other developed country — often two to ten times more for the same medication. This pricing gap is not a secret: it is documented in government reports, academic studies, and congressional hearings. Understanding why it exists, how large it is, and what the 2026 pharmaceutical tariff's MFN mechanism is attempting to do about it is essential context for any patient trying to understand their drug costs.
The Data: US vs Other Countries
Research from the RAND Corporation, the Commonwealth Fund, and government sources consistently shows:
- US brand name drug prices are 2.56x higher than comparable countries on average (RAND, 2021)
- US prices vs UK: US pays approximately 3–4x more for brand name drugs
- US prices vs Japan: US pays approximately 1.5–2.5x more
- US prices vs Germany/EU: US pays approximately 2–3x more
- Generic drug prices: Much closer globally — US generics are often competitive or cheaper than other countries
Specific examples of brand name drug price differences:
- Humira (adalimumab): ~$7,000/month US list price vs ~$1,800/month in Germany
- Eliquis (apixaban): ~$600/month US vs ~$100/month UK
- Ozempic (semaglutide): ~$900/month US vs ~$80/month Germany
- Lantus (insulin glargine): ~$300/month US vs ~$40/month France
Why Are US Drug Prices So Much Higher?
### No Central Price Negotiation
The most fundamental difference: the US, until very recently, did not negotiate drug prices for the largest payer in the system — Medicare. The UK has the NICE (National Institute for Health and Care Excellence), which evaluates clinical and cost effectiveness and negotiates prices accordingly. Germany has the AMNOG process. Japan has a national pricing system.
The Inflation Reduction Act (2022) introduced limited Medicare drug price negotiation starting in 2026 for a small set of drugs. But for most drugs, manufacturers still set US prices freely.
### Patent Protection and Market Exclusivity
US patent law provides strong IP protection — manufacturers can maintain monopoly pricing for years. While other countries also respect drug patents, their price negotiation systems prevent manufacturers from charging US-level prices during exclusivity.
### Pharmacy Benefit Manager (PBM) System
The US drug distribution system runs through PBMs — intermediaries that negotiate rebates with manufacturers. This creates a system of list prices (high) and net prices (lower, after rebates) that is opaque and often serves payer interests more than patient interests. Patients paying out of pocket pay off the high list price, not the net price.
### Pharmaceutical R&D Cost Recovery
Drug companies often justify US prices partly as necessary to recover global R&D costs — arguing that other countries' price controls are effectively subsidized by US patients. There is some validity to this argument, but critics note that US prices are far above what cost-of-R&D justifications would require.
UK Drug Pricing: How It Works
The UK's National Health Service (NHS) negotiates drug prices through the Pharmaceutical Price Regulation Scheme (PPRS) and, more recently, the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS). NICE evaluates cost-effectiveness using the Quality-Adjusted Life Year (QALY) framework — drugs that do not demonstrate value are not covered or are covered at reduced prices.
The result: UK drug prices are significantly lower than US prices for brand name drugs. Generic drug prices in the UK are also regulated differently than in the US, with Drug Tariff pricing setting reimbursement for generics dispensed by NHS pharmacies.
Japan Drug Pricing
Japan operates a national drug pricing system where the government sets official drug prices (薬価, yakka) for all drugs covered by national health insurance. Prices are revised every two years and typically decrease over time. Japan's prices for brand name drugs are generally 1.5–2.5x lower than US prices.
Notably, the 2026 US tariff gives Japan-manufactured drugs a 15% rate rather than 100% — acknowledging Japan as a trusted manufacturing partner. This country-specific rate reflects the tariff's geopolitical dimensions.
The MFN Deal's Intent
The MFN (Most Favored Nation) deals signed by 13 pharmaceutical companies under the 2026 tariff are designed to bridge the US-global pricing gap. MFN pricing means companies must offer Americans their lowest global price — in theory closing the gap between US and European/Japanese prices for those manufacturers' drugs.
Whether MFN deals achieve meaningful price reductions in practice remains to be seen. But they represent a direct acknowledgment that the US pricing gap is real — and that US government leverage (tariff threat) can be used to address it.
Check your drug's status — including whether your manufacturer has an MFN deal — using the drug search tool.